Abstract: The present disclosure provides for peptides derived from membrane-anchored ubiquitin-fold proteins (MUB), particularly those containing a Lap-Bar-Lopp motif, for use in inhibiting ubiquitinylation.

Abstract: The present invention generally relates to various polycyclic aromatic selenoxide compounds, methods for preparing these compounds, and methods of us these and other compounds to generate ground state atomic oxygen.

Abstract: The present disclosure relates to vaccine formulations and their use in treating and preventing Chagas Disease.

Abstract: Disclosed herein are methods for transferring carbon nanotubes on a hydrogel scaffold. Carbon nanotubes are formed on a substrate and directly transferred onto a hydrogel surface. Carbon nanotubes transferred according to the present disclosure can be used in tissue engineering applications and electrode coating applications.

Abstract: Disclosed are methods and compositions for reduced immunogenic proteins used in enzyme replacement therapy for lysosomal storage disorders. More specifically disclosed are genetically engineered variants of N-acetylgalactosamine-6-sulfatase (GALNS), which are less immunogenetic then wild-type GALNS, but maintain enzymatic activity, and may be used to treat Mucopolysaccharidosis IVA (Morquio A disease, MPS IVA).

Abstract: In some aspects, the present disclosure provides compounds of the formula: (I) or (II) wherein the variables are as defined herein. In some embodiments, these compounds may be used to treat cancer or other hyperproliferative diseases, as well as atherosclerosis and coronary artery disease.

Abstract: The present disclosure provides methods of treating a patient comprising administering a p38 inhibitor for the treatment of FSHD. In some embodiments, the present methods comprise using one or more p38 inhibitors as a therapeutic agent for the treatment of FSHD patients including patients who are being treated with one or more palliative treatments such as therapy and/or agents which lead to increased muscle mass.

Abstract: The present invention generally concerns a nano-enhanced explosive that is integrated at many points across an explosive train. More specifically, a nano-enhanced explosive is formed when a nanocomposite we call nMx is combined with a secondary high explosive. nMx is made of Li3AlH6 nanoparticles, elemental Al nanoparticles, an amount of Ti metal, and a nanoscale organic layer having unique burning profiles that lend energy to the explosive process including increased shockwave propagation through a chemical explosive and increased temperatures and gaseous pressure build up and release in and about the same. Our nano-enhanced explosive can be integrated at various points across an explosive train, e.g. use within a detonation cord (fuse), or as a detonation charge (initiator), or as the main charge, where the use of the nano-enhanced explosive can be characterized by the energy lent to projectiles from munitions, bubbles formed by underwater explosive trains, or blast profiles.

Abstract: The present disclosure provides methods of preparing heterostructures of two or more transition metal dichalcogenides on a surface in a pattern in which the method does not require a mask or blocking agent to create a pattern on the surface. Also provided herein are ink compositions which are used in the methods described herein and include precursor materials that generate these transition metal dichalcogenides.

Abstract: The present invention generally relates to various dibenzothiophene compounds, processes for preparing these compounds, and uses of these compounds. The present invention also relates to cell imaging agents comprising one or more of the dibenzothiophene compounds and processes for imaging a cell using the compounds. The present invention further relates to methods of producing ground state atomic oxygen.

Abstract: Systems and methods for inhibiting atherosclerosis using FoxP3+ CD8 T-cells (TcREG). Osteoclasts are induced to produce FoxP3+ CD8 T-cells (TcREG) through introduction of a low-dose of a RANK agonist such as RANKL. The RANKL was found to best work when provided in accordance with a schedule resulting in a pulsed administration.

Abstract: In one aspect, the present disclosure describes new estrogen receptor-related orphan receptor (EER) inverse agonist compounds. Also described are pharmaceutical formulations, methods of synthesis and uses thereof.

Abstract: The present invention provides a system for conservation and efficient use of energy through controlling and monitoring of devices. At least one processing controller connected to a sensor and a device, the processing controller configured to receive the ambient data from the sensor and operating parameters from the device; a user module configured to IO receive input parameters from a plurality of users; a central processing module, connected to the structure, the user module, and the admin module through wired and/or wireless connection, the central processing module configured to process the data received from the processing controller adapted in the zone of the structure and generate the optimum parameters for operating the device adapted in the zone to the structure.

Abstract: The disclosure provides for new epidermal growth factor (EGF)-based reagents that have been modified by fatty acid conjugation. Method of using such agents to treatment Short Bowel Sydnrome (SBS) are also described.

Abstract: Disclosed are therapeutic compositions, methods of preparing, and methods use for the treatment of infectious diseases and cancer. More specifically, Natural Killer Cell (NK Cell)-derived exosomes are demonstrated as potent therapeutic agents that can kill tumor cells in vivo, but do not kill normal cells. The exosomes can also be used to treat infectious disease.

Abstract: In one aspect, the present disclosure provides methods of treating a bacterial infection using an inhibitor of the nucleotidyltransferase superfamily enzyme. In some embodiments, the compounds have one of the following formulas (I), (II), (III), or (IV) wherein R1, R2, and R3 are as defined herein or a pharmaceutically acceptable salt thereof. The compounds may be used to treat a bacterial infection including an infection of Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumoniae, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species.

Abstract: The present disclosure relates to novel compounds, pharmaceutical compositions, and methods for treating or preventing microbial infection caused by parasites or bacteria, such as Plasmodium falciparum or related Plasmodium parasite species and Mycobacterium tuberculosis or related Mycobacterium bacteria species. The compounds are ?,?-unsaturated analogs of fosmidomycin and can inhibit deoxyxylulose phosphate reductoisomerase (Dxr) in many microbes, such as P. falciparum.

Abstract: The present disclosure relates to the SALL1 tumor suppressor. Methods of employing SALL1 to treat cancer, as well as the underlying mechanism by which this occurs, also are described.

Abstract: The present disclosure provides pharmaceutical agents of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such pharmaceutical agents. Methods of using the pharmaceutical agents for the treatment of a variety of diseases and disorders are also provided.

Abstract: Disclosed are compounds of the formula (I) and (II): which are A3 adenosine receptor agonists, pharmaceutical compositions comprising such compounds, and a method of use of these compounds, wherein X, Y, Z, R2-R6, and R103-R106 are as defined in the specification. These compounds are selective to the A3 receptor, and are contemplated for use in the treatment or prevention of a number of diseases or conditions, for example, neuropathic pain.